# Danaher: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Danaher Corporation · NYSE: DHR · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 19, 2026

This is the plain-text version of https://cityfort.co/stocks/danaher. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Danaher: how the business works", with the page URL.

## The 30-second summary

Danaher makes equipment, consumables and tests for drugmakers, research labs and hospitals, with sales of $24,568 million in FY2025. Recurring purchases of consumables, service and leases were $81.9 of every $100 of those sales, and Diagnostics was the largest segment at 40.5%. Borrowings rose from $18,418 million at Dec 31, 2025 to $26,482 million at Sep 25, 2026, after it bought Masimo for about $9.8 billion.

## 5 points

- **What it sells:** Danaher sells equipment, consumables and tests to drugmakers, research labs and hospitals, with sales of $24,568 million in FY2025. [S1]
- **Who pays it:** Danaher discloses no split by customer; by region, North America paid 42.2% of FY2025 sales, high-growth markets 28.6%, Western Europe 24.2% and other developed markets 5.1%. [S1]
- **What it keeps from $100:** Of every $100 that came in during FY2025, Danaher kept $14.6 as net income from continuing operations, after $562 million of impairments; making and delivering products took $40.8. [S1]
- **Where the operating profit comes from:** In FY2025, Diagnostics earned $2,650 million of segment operating profit, Biotechnology $1,864 million and Life Sciences $520 million, after $446 million of Life Sciences impairments. [S1]
- **The one thing to watch:** Borrowings rose from $18,418 million at Dec 31, 2025 to $26,482 million at Sep 25, 2026, after the $9.8 billion Masimo purchase. [S3, S1]

## What does Danaher sell?

Danaher makes the equipment, supplies and tests that drugmakers, research labs and hospitals use. It runs more than 15 operating companies in three segments.

- **Biotechnology (Cytiva, Pall):** Equipment, consumables and services drugmakers use to develop and make biological medicines, such as antibodies, insulin, vaccines and cell and gene therapies. [S1]
- **Life Sciences:** Lab instruments such as microscopes, mass spectrometers and flow cytometers, plus DNA and protein products from IDT and Abcam. [S1]
- **Diagnostics:** Analyzers and tests for hospital and clinical labs from Beckman Coulter, Cepheid, Radiometer and Leica Biosystems; Masimo pulse oximeters and patient monitors since Jun 2026. [S1, S3]

## Who pays Danaher?

- **Drugmakers and contract manufacturers:** Buy bioprocessing equipment and consumables to develop and make biological medicines. [S1]
- **Research labs and universities:** Buy microscopes, mass spectrometers and other instruments, and the consumables they use. [S1]
- **Hospitals, reference labs and doctors' offices:** Buy diagnostic analyzers and tests and, since Jun 2026, Masimo patient monitors. [S1, S3]
- **Customer concentration:** Danaher does not disclose revenue by customer. Its 10-K says credit risk from customers is limited because they are diverse. [S1]

## Where the money went (FY2025)

1. In FY2025 customers paid Danaher $24,568 million, and it earned $30 million of interest on its cash.
2. Making and delivering the products cost $10,045 million, leaving $14,523 million of gross profit.
3. Selling, running the company and research took $9,833 million.
4. Other expenses, interest and income tax took $1,120 million, leaving $3,600 million of net income.
5. Another $14 million from discontinued operations (Veralto) made total net income $3,614 million.

Sources: S1.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year); quarters end on a Friday near the end of March, June and September. — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 (restated) | 24,802 | 8,439 | 34.0% | 6,433 | 25.9% | 8.61 | 8,358 | 1,240 | 7,118 | S27, S29 |
| FY2022 (restated) | 26,643 | 9,668 | 36.3% | 7,209 | 27.1% | 9.66 | 8,519 | 1,118 | 7,401 | S2, S28 |
| FY2023 | 23,890 | 7,368 | 30.8% | 4,764 | 19.9% | 6.38 | 7,164 | 1,383 | 5,781 | S27 |
| FY2024 | 23,875 | 7,215 | 30.2% | 3,899 | 16.3% | 5.29 | 6,688 | 1,392 | 5,296 | S2 |
| FY2025 | 24,568 | 7,137 | 29.0% | 3,614 | 14.7% | 5.05 | 6,416 | 1,156 | 5,260 | S1 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 25, 2026, US$ million)

Net debt of $20.8 billion on Sep 25, 2026 equals about 3.2 years of FY2025 operating cash flow (Cityfort calculation from the Q3 FY2026 10-Q and FY2025 10-K). [S3, S1]

| Item | Value |
| --- | --- |
| Total debt | 26,482 |
| Cash and investments | 5,682 |
| Net debt (debt minus cash) | 20,800 |
| Net worth (shareholders' money) | 53,621 |
| Debt to equity (times) | 0.49 |

- Total debt is borrowings, excluding lease liabilities, from Note 11 of the Q3 FY2026 10-Q.
- Net debt is a Cityfort calculation from the Q3 FY2026 10-Q: $26,482 million of borrowings minus $5,682 million of cash.
- Borrowings rose from $18,418 million at Dec 31, 2025, after the $9.8 billion Masimo purchase in Jun 2026.
- Danaher has a $5.0 billion unsecured revolving credit facility that expires on Aug 11, 2028 (FY2025 10-K).

## Who owns Danaher? (as of Mar 1, 2026)

The 2026 proxy's table, as of Mar 1, 2026, shows Danaher's 21 directors and executive officers as a group holding 76,782,313 shares, or 10.8%; most belong to the two Rales brothers. [S7, S3]

- Officers and directors (as a group), shares: 10.8%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (Shares outstanding on Oct 15, 2026 (Q3 FY2026 10-Q cover). Danaher has one class of common stock, listed on the NYSE.) | 703.5 | 1 | — | — | Yes | S3 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 8.6% | — | Dec 31, 2025 | 2026 proxy figure from a Schedule 13G filed Jan 30, 2026: 60,973,344 shares. | S7 |
| BlackRock, Inc. | 7.2% | — | Dec 31, 2023 | 2026 proxy figure from a Schedule 13G filed Jan 26, 2024: 50,771,463 shares. No newer filing is held for this page. | S7 |
| Steven M. Rales (co-founder, Chairman) | 6.0% | — | Mar 1, 2026 | 42,240,297 shares, including 31,000,000 held through companies he controls. | S7 |
| Mitchell P. Rales (co-founder) | 4.7% | — | Mar 1, 2026 | 33,001,391 shares, including 26,171,000 held through companies he controls. | S7 |

## What could go wrong

### Weaker respiratory testing

Diagnostics core sales grew 0.5% in Q3 FY2026; respiratory testing took 6.5 points off. In Apr 2026 Blair cited a lighter-than-typical respiratory season at Cepheid. [S8, S10]

What to watch: The respiratory testing line in each quarterly growth table.

### More debt after two 2026 deals

Borrowings, excluding lease liabilities, rose from $18,418 million at Dec 31, 2025 to $26,482 million at Sep 25, 2026. The 10-K lists debt and credit ratings as a risk factor. [S1, S3]

What to watch: Net debt in the FY2026 10-K.

### Falling sales in China

Sales to China fell from $3,143 million in FY2023 to $2,631 million in FY2025, or 10.7% of FY2025 sales. The 10-K says China core revenue fell by a mid-single-digit percentage in 2025. [S1]

What to watch: China sales in the FY2026 10-K.

### Write-downs of acquired businesses

Goodwill from past deals was $47,315 million at Sep 25, 2026, about half of total assets of $93,281 million. Danaher booked $562 million of impairments in FY2025, $446 million of them in Life Sciences. [S1, S3]

What to watch: Impairment charges in each 10-Q.

### Shareholder lawsuits over bioprocessing statements

A 2023 class action alleges Danaher made misleading statements about bioprocessing revenue between Jan 2022 and Oct 2023. Danaher says it recorded a settlement liability and an offsetting insurance receivable; the court granted final approval at a Sep 2026 hearing and said a written order would follow. New derivative suits on the same allegations were filed from Mar 2026. [S3]

What to watch: The court's written order and the derivative cases.

### Tariffs and trade rules

Danaher said new tariffs cost it less than $300 million more in 2025, largely offset. Tariff refunds to customers reduced Q3 FY2026 sales growth by 1.0 point. [S1, S8]

What to watch: Tariff costs in the FY2026 10-K.

### Absorbing Masimo and StatLab

Danaher paid about $9.8 billion for Masimo in Jun 2026 and about $1.4 billion for StatLab in Sep 2026. Diagnostics operating profit was $614 million in Q3 FY2026, against $665 million a year earlier, on 17.0% higher sales. [S3, S8]

What to watch: Diagnostics operating profit per $100 of sales.

## What to watch

Next: Q4 FY2026 results, Date not announced yet.

- **Respiratory testing:** Danaher said on Oct 21, 2026 that it expects respiratory testing to take about 1.5 points off Q4 FY2026 core growth. In Q3 FY2026 it took 6.5 points off Diagnostics core growth.
- **Diagnostics profit after Masimo and StatLab:** Diagnostics operating profit was $614 million in Q3 FY2026, against $665 million a year earlier. StatLab, bought for about $1.4 billion, joins the segment from Q4 FY2026.
- **Debt after the 2026 deals:** Borrowings were $26,482 million on Sep 25, 2026, against $18,418 million at Dec 31, 2025. The FY2026 10-K will show the year-end figure.
- **A new CEO:** Julie Sawyer Montgomery became CEO on Oct 1, 2026, so Q4 FY2026 is her first full quarter in the role. Rainer Blair stays as Senior Advisor to Dec 31, 2026.

## Sources

- S1: FY2025 Form 10-K. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000062/dhr-20251231.htm (published Feb 24, 2026)
- S2: FY2024 Form 10-K. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361625000043/dhr-20241231.htm (published Feb 20, 2025)
- S3: Q3 FY2026 Form 10-Q (quarter ended Sep 25, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000199/dhr-20260925.htm (published Oct 21, 2026)
- S4: Q2 FY2026 Form 10-Q. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000161/dhr-20260626.htm (published Jul 21, 2026)
- S5: Q1 FY2026 Form 10-Q. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000107/dhr-20260327.htm (published Apr 21, 2026)
- S6: Q3 FY2025 Form 10-Q. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361625000182/dhr-20250926.htm (published Oct 21, 2025)
- S7: 2026 proxy statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000101/dhr-20260325.htm (published Mar 25, 2026)
- S8: Q3 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000201/dhr-20261021xex991.htm (published Oct 21, 2026)
- S9: Q2 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000163/dhr-20260721xex991.htm (published Jul 21, 2026)
- S10: Q1 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000109/dhr-20260421xex991.htm (published Apr 21, 2026)
- S11: Q4 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000004/dhr-20260128xex991.htm (published Jan 28, 2026)
- S12: Q3 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361625000180/dhr-20251021xex991.htm (published Oct 21, 2025)
- S13: Q2 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361625000152/dhr-20250722xex991.htm (published Jul 22, 2025)
- S14: Q1 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361625000090/dhr-20250422xex991.htm (published Apr 22, 2025)
- S15: Q4 FY2024 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361625000004/dhr-20250129xex991.htm (published Jan 29, 2025)
- S16: 8-K filed Feb 17, 2026 (Masimo merger agreement, Item 8.01). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000119312526053124/d110495d8k.htm (published Feb 17, 2026)
- S17: 8-K filed Apr 17, 2026 (Items 1.01, 2.03 financing). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000119312526160383/d56203d8k.htm (published Apr 17, 2026)
- S18: 8-K filed Apr 29, 2026 (Item 1.01). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000119312526191608/d107133d8k.htm (published Apr 29, 2026)
- S19: 8-K filed Jun 3, 2026 (Item 2.03 note purchase agreement). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000119312526255555/d63873d8k.htm (published Jun 3, 2026)
- S20: 8-K filed Aug 3, 2026 (CEO succession, Item 5.02). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000119312526330652/d161342d8k.htm (published Aug 3, 2026)
- S21: J.P. Morgan healthcare conference presentation (8-K filed Jan 12, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361626000002/selecteddanaherpresentat.htm (published Jan 12, 2026)
- S22: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361625000153/0000313616-25-000153-index.htm (published Jul 22, 2025)
- S23: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361625000088/0000313616-25-000088-index.htm (published Apr 22, 2025)
- S24: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361624000220/0000313616-24-000220-index.htm (published Oct 22, 2024)
- S25: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361624000186/0000313616-24-000186-index.htm (published Jul 23, 2024)
- S26: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361624000102/0000313616-24-000102-index.htm (published Apr 23, 2024)
- S27: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361624000052/0000313616-24-000052-index.htm (published Feb 21, 2024)
- S28: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361623000087/0000313616-23-000087-index.htm (published Feb 22, 2023)
- S29: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/313616/000031361622000061/0000313616-22-000061-index.htm (published Feb 23, 2022)
